Relonchem Limited receives Marketing Authorization from UKMHRA for its products

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) has announced that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization from UKMHRA for the below mentioned products:

1) Fluoxetine 10mg Capsules

2) Fluoxetine 30mg Capsules

3) Fluoxetine 60mg Capsules

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 220.90 as compared to the previous close of Rs. 220.50. The total number of shares traded during the day was 294070 in over 5148 trades.

The stock hit an intraday high of Rs. 223.85 and intraday low of 215.40. The net turnover during the day was Rs. 64724503.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 Relonchem UKMHRA MarketingAuthorization FluoxetineCapsules